+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results



Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results



Circulation 104(1): 39-45



Background: Previous studies have shown disappointing results for immunosuppressive treatment in patients with dilated cardiomyopathy. Therefore, we studied the effectiveness of such therapy in patients with HLA upregulation on biopsy. Methods and Results: Of 202 patients with dilated cardiomyopathy, 84 patients with increased HLA expression were randomized to receive either immunosuppression or placebo for 3 months; they were then followed for 2 years. After 2 years, there were no significant differences in the primary end point (a composite of death, heart transplantation, and hospital readmission) between the 2 study groups (22.8% for the immunosuppression group and 20.5% for the placebo). The secondary efficacy end point included changes in ejection fraction, end-diastolic diameter, end-diastolic volume, end-systolic volume and NYHA class; left ventricular ejection fraction increased significantly in the immunosuppression group compared with the placebo group (95% CI, 4.20 to 13.12; P<0.001) after 3 months of follow-up. The early favorable effects of immunosuppressive therapy on left ventricular volume, left ventricular diastolic dimension, and New York Heart Association class were also present. This improvement was maintained in the immunosuppression group at 2 years (ejection fraction: 95% CI, 6.94 to 19.04; P<0.001). In addition, on the basis of the protocol-specified definition of improvement, 71.8% patients in the immunosuppression group versus 20.9% patients in the placebo group met the criteria of improvement after 3 months (P<0.001). At the end of the follow-up period, 71.4% patients from the immunosuppression group versus 30.8% patients from the placebo group were improved (P=0.001). Conclusions: These data demonstrate a long-term benefit of immunosuppressive therapy in patients with dilated cardiomyopathy and HLA upregulation on biopsy specimens. Thus, restoration of immunosuppressive therapy for such patients should be considered.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011243767

Download citation: RISBibTeXText

PMID: 11435335

DOI: 10.1161/01.cir.104.1.39


Related references

Prospective randomized controlled trial of anti inflammatory therapy in dilated cardiomyopathy a three and nine month follow up. Circulation 76(4 Part 2): IV-460, 1987

Effect of short-term immunosuppressive therapy on chronic inflammatory cardiomyopathy Two-year follow-up results. European Heart Journal 21(Abstract Suppl.): 489, August-September, 2000

Immunosuppressive treatment for inflammatory cardiomyopathy: meta-analysis of randomized controlled trials. International Heart Journal 46(1): 113-122, 2005

Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study). Arquivos Brasileiros de Cardiologia 74(3): 233-242, 2000

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial. American Heart Journal 152(4): 713.E1, 2006

Evolution of dilated cardiomyopathy (DCM) from idiopathic hypertrophic cardiomyopathy (IHCM) vs. inflammatory dilated cardiomyopathy (DCMi): a rare case of sudden death in an 8-year-old boy. Pathology Research and Practice 200(5): 411-5; Discussion 417-21, 2004

Evolution of dilated cardiomyopathy from idiopathic hypertrophic cardiomyopathy vs inflammatory dilated cardiomyopathy a rare case of sudden death in an 8-year-old boy. Pathology Research & Practice 200(5): 411-415, 2004

The Natural History Of Nocturia Among Men Allocated To Placebo: Results From A Randomized Controlled Trial With One Year Follow-Up. The Journal of Urology 187(4): e502-e503, 2012

Evolution of dilated cardiomyopathy from idiopathic hypertrophic cardiomyopathy vs inflammatory dilated cardiomyopathy a rare case of sudden death in an 8-year-old boy by R Dettmeyer, P Schmidt, R Kandolf and B Madea, Pathol Res Pract 200 411-415. Pathology Research & Practice 200(5): 417-421, 2004

A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. Journal of Veterinary Internal Medicine 16(3): 255-261, 2002

A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. Praktische Tierarzt 84(9): 658-673, 2003

Evolution of dilated cardiomyopathy (DCM) from idiopathic hypertrophic cardiomyopathy (IHCM) vs. inflammatory dilated cardiomyopathy (DCMi): a rare case of sudden death in an 8-year-old boy by R. Dettmeyer, P. Schmidt, R. Kandolf and B. Madea, Pathol. Res. Pract. 200 (2004) 411415. Pathology - Research and Practice 200(5): 417-421, 2004

Azathioprine in relapsing remitting multiple sclerosis 2 year follow up results of a randomized double masked placebo controlled trial. Neurology 40(4 Suppl. 1): 284, 1990

Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. European Heart Journal 21(15): 1259-1264, 2000

Nesiritide improves hemodynamics in children with dilated cardiomyopathy: A prospective randomized double-blinded placebo-controlled study. 2007